COLD + SINUS DAYTIME TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
19-10-2020
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
Pieejams no:
VITA HEALTH PRODUCTS INC
ATĶ kods:
M01AE51
SNN (starptautisko nepatentēto nosaukumu):
IBUPROFEN, COMBINATIONS
Deva:
200MG; 30MG
Zāļu forma:
TABLET
Kompozīcija:
IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
10/20/24/40/50/72/96/100
Receptes veids:
OTC
Ārstniecības joma:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktu pārskats:
Active ingredient group (AIG) number: 0222394001; AHFS:
Autorizācija statuss:
APPROVED
Autorizācija datums:
2011-02-08
Produkta apraksts
PRODUCT MONOGRAPH
COLD + SINUS DAYTIME
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
COLD + SINUS NIGHTTIME
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
and Chlorpheniramine Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
October 19, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control # 239435
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
5
ADVERSE REACTIONS
.......................................................................................................................
13
DRUG INTERACTIONS
........................................................................................................................
23
DOSAGE AND ADMINISTRATION
....................................................................................................
27
OVERDOSAGE
......................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
31
STORAGE AND STABILITY
...............................................................................................................
36
SPECIAL HANDLING INSTRUCTIONS
....................................
Izlasiet visu dokumentu
